"Designing Growth Strategies is in our DNA"

Autism – Pipeline Review, 2019

Region : Global | Published Date: Upcoming | Report ID: FBI101275| Status : Pipeline



Autism, also referred to as Autism Spectrum Disorder (ASD), is used to refer to a complex neurobehavioral condition which has a broad range of symptoms which challenges such as social skills, speech, and nonverbal communication and repetitive behaviors. Some of the indicators of autism include persistent preference of solitude, avoidance of eye contact, loss of previously acquired speech or social skills, difficulty in understanding others’ emotions, restricted interests, delayed language development, and repetitive behaviors.

Autism can be caused by a variety of factors which include genetic risk factors such as autism that runs in families, advanced ages of the child’s parents, pregnancy and birth complications, the pregnancies that are spaced less than a year apart and the differences in brain biology of the child. For the treatment and management of the symptoms of autism, an approach including various types of treatment is often adopted. In terms of medications, Risperidone (Risperdal) is the only FDA approved the drug for the treatment of autism spectrum disorder (ASD) in children. But medical professionals often prescribe other medications such as anti-depressants to deal with the symptoms. Therapies such as play therapies, behavioral therapies, and sensory therapies can be administered.

Pharmaceutical companies and various research institutes have been focusing on studying and developing new treatment options for Autism. For instance; Balovaptan (RO5285119), which is being studied by F. Hoffmann-La Roche Ltd, is currently in phase-2 clinical trials for the Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants with Autism Spectrum Disorder (ASD).

To get details on market share, speak to our analyst

At present around 73% of the pipeline candidates for Autism are in the phase-1 and phase-2 stage combined. Majority of the studies are sponsored by industry and governmental institutions.

Report Description

The report on ‘Autism – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Autism. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Autism.

The report on ‘Autism – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

  • Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target

  • Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration

  • Overview of dormant and discontinued pipeline products

  • Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products

  • Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

  • All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.

  • Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

  • Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Autism

  • Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players

  • Identify the focus of leading players in relation to R&D for Autism

  • Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business

  • Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary


  • 2050

Healthcare Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.